Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timothy M Clay

Showing results (41-50 of 71) with videos related to

Pageof 8
Sort By:
Cancer Immunology, Immunotherapy : CII|March 5, 2009
Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine ConsortiumCedrik Michael Britten, Sylvia Janetzki, Leah Ben-Porat, et al.
International Journal of Gastrointestinal Cancer|March 13, 2003
The feasibility and safety of immunotherapy with dendritic cells loaded with CEA mRNA following neoadjuvant chemoradiotherapy and resection of pancreatic cancerMichael A Morse, Smita K Nair, David Boczkowski, et al.
Journal of Hematotherapy & Stem Cell Research|August 31, 2002
Dendritic cell recovery following nonmyeloablative allogeneic stem cell transplantsMichael A Morse, David Rizzieri, Timothy T Stenzel, et al.
Journal of Translational Medicine|September 8, 2007
Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2Michael A Morse, Amy Hobeika, Takuya Osada, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|September 19, 2019
The Landscape of Early Clinical Gene Therapies outside of OncologyLaure Rittié, Takis Athanasopoulos, Miguel Calero-Garcia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 9, 2011
MHC class I-presented tumor antigens identified in ovarian cancer by immunoproteomic analysis are targets for T-cell responses against breast and ovarian cancerMichael A Morse, Angeles A Secord, Kimberly Blackwell, et al.
Cancer Research|May 3, 2011
Antihelminth compound niclosamide downregulates Wnt signaling and elicits antitumor responses in tumors with activating APC mutationsTakuya Osada, Minyong Chen, Xiao Yi Yang, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 12, 2005
Evasion of immune responses to introduced human acid alpha-glucosidase by liver-restricted expression in glycogen storage disease type IILuis M Franco, Baodong Sun, Xiaoyi Yang, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 20, 2009
Immunomodulatory gene therapy prevents antibody formation and lethal hypersensitivity reactions in murine pompe diseaseBaodong Sun, Michael D Kulis, Sarah P Young, et al.
Cancer Immunology, Immunotherapy : CII|August 28, 2007
Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI)Sylvia Janetzki, Katherine S Panageas, Leah Ben-Porat, et al.
Pageof 8

Showing results (41-50 of 71) with videos related to

Sort By:
Pageof 8
Cancer Immunology, Immunotherapy : CII|March 5, 2009
Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine ConsortiumCedrik Michael Britten, Sylvia Janetzki, Leah Ben-Porat, et al.
International Journal of Gastrointestinal Cancer|March 13, 2003
The feasibility and safety of immunotherapy with dendritic cells loaded with CEA mRNA following neoadjuvant chemoradiotherapy and resection of pancreatic cancerMichael A Morse, Smita K Nair, David Boczkowski, et al.
Journal of Hematotherapy & Stem Cell Research|August 31, 2002
Dendritic cell recovery following nonmyeloablative allogeneic stem cell transplantsMichael A Morse, David Rizzieri, Timothy T Stenzel, et al.
Journal of Translational Medicine|September 8, 2007
Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2Michael A Morse, Amy Hobeika, Takuya Osada, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|September 19, 2019
The Landscape of Early Clinical Gene Therapies outside of OncologyLaure Rittié, Takis Athanasopoulos, Miguel Calero-Garcia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 9, 2011
MHC class I-presented tumor antigens identified in ovarian cancer by immunoproteomic analysis are targets for T-cell responses against breast and ovarian cancerMichael A Morse, Angeles A Secord, Kimberly Blackwell, et al.
Cancer Research|May 3, 2011
Antihelminth compound niclosamide downregulates Wnt signaling and elicits antitumor responses in tumors with activating APC mutationsTakuya Osada, Minyong Chen, Xiao Yi Yang, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 12, 2005
Evasion of immune responses to introduced human acid alpha-glucosidase by liver-restricted expression in glycogen storage disease type IILuis M Franco, Baodong Sun, Xiaoyi Yang, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 20, 2009
Immunomodulatory gene therapy prevents antibody formation and lethal hypersensitivity reactions in murine pompe diseaseBaodong Sun, Michael D Kulis, Sarah P Young, et al.
Cancer Immunology, Immunotherapy : CII|August 28, 2007
Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI)Sylvia Janetzki, Katherine S Panageas, Leah Ben-Porat, et al.
Pageof 8